Zhou Q, Jiang X, Li K. et al. Synthesis, characterization and in situ intestinal absorption of different molecular weight scutellarin-PEG conjugates[J]. Pharmazie, 2006, 61(8):660.
[7]
Zhong Haijun, Deng Yingjie, Wang Xiumin, et al. Multivesicular liposome formulation for the sustained delivery of breviscapine[J]. Int J Pharm, 2005, 30(1):15.
[8]
Zhang J L, Che Q M, Li S Z, et al. Study on metabolism of scutellarin in rats by HPLC-MS and HPLC-NMR[J]. J Asian Nat Prod Res, 2003, 5(4): 249.
Cao F, Zhang H, Guo J.et al. Mrp2-related efflux of scutellarin in the intestinal absorption in rats[J].Pharmazie, 2008, 63(1):75.
[12]
Hao X, Chen G, Yu J E, et al. Study on the role of hepatic first-pass elimination in the low oral bioavailability of scutellarin in rats [J].Pharmazie, 2005,60(6)447.
Liu Xiaobin, Ye Junxiao, et al. Pulmonary delivery of scutellarin solution and mucoadhesive particles in rats [J]. J Asian Nat Prod Res, 2008, 5(4): 249.
[18]
Wang M, Fang L, Ren C, et al. Effect of ion-pairing and enhancers on scutellarin skin permeability[J]. J Pharm Pharmacol, 2008,60(4):429.
Fei Xiong, Hao Wang, Ji Cheng, et al. Determination of scutellarin in mouse plasma and different tissues by high-performance liquid chromatography[J].J Chromatogr B, 2006,835(1/2):114.
[26]
杨炳华，钟大放. 野黄芩苷的药物动力学及代谢研究[D]. 沈阳 :沈阳药科大学,2004.
[27]
Lv W L, Guo J X, Jin L, et al .distribution of liposornal breviscapine in brain following intravenous injection in rats[J].Int I Pharm,2005,306(1/2):99.
[28]
Chen X, Cui L, Duan X, et al. Pharmacokinetics and metabolism of the flavonoid scutellarin in humans after a single oral administration[J].Drug Metab Dispos, 2006,34(8):1345.
[29]
Gao H, Wang Z, Tian J. Pharmacokinetics and met abolites of scutellarin in normal and model rats[J].Acta Pharm Sin, 2005,40(11):1024.
